However, the pan-glutaminase inhibitor compound 968 targets protein forms of both GLS1 and GLS2 (LGA) and has recently been utilized to suppress luminal-type breast cancer growth by inhibiting the previously underappreciated LGA [98]. This evidence concerns the gene GLS and breast carcinoma.